



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS GRANTED 1.6 MILLION EURO IN RESEARCH TAX CREDIT

Paris, September 11, 2012 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases announced today that it has received 1.6 million Euros in research tax credit for R&D expenses incurred in 2011.

“Investment is key for innovative companies like NEOVACS. R&D makes up for over 75% of our expenses. The funds that we receive today strengthen our financial position, and show real public support for research and innovation in auto-immune diseases.” commented Guy Charles Fanneau de La Horie, CEO of NEOVACS.

NEOVACS announced in January 2012 very encouraging results of the Phase IIa clinical trial with TNF-Kinoid in rheumatoid arthritis. A second Phase II clinical trial is currently ongoing with TNF-Kinoid in Crohn’s Disease. Interim results were presented last June and final results are expected before the end of the year. The funds received today will be dedicated to future clinical development of the company.

About NEOVACS

NEOVACS is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The company’s proprietary technology covered by five patent families that run until at least 2023 has generated to date 2 product candidates in 3 severe diseases: TNF-Kinoid for Rheumatoid Arthritis and Crohn’s Disease and IFN α -Kinoid for Lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

Presse – ALIZE RP

Caroline Carmagnol
+33 (0)1 42 68 86 43
caroline@alizerp.com

NEOVACS

Nathalie Trépo
+33 0 1 53 10 93 14
ntrepo@neovacs.com

Investors / NewCap

Axelle Vuillermet
+ 33 (0) 1 44 71 94 93
avuillermet@newcap.fr